CIK 0001321834 · Non-accelerated filer<br>Smaller reporting company
Q/C TECHNOLOGIES, INC.
Sign in to watch- Ticker
- QCLS
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 856-848-8698
- Business address
- 1185 AVENUE OF THE AMERICAS, SUITE 249, NEW YORK, NY, 10036
- Former names
- Q/C TECHNOLOGIES, INC., TNF Pharmaceuticals, Inc., MyMD Pharmaceuticals, Inc., Akers Biosciences, Inc., Akers Biosciences Inc
- 8-K Event Executive or director change · Shareholder vote results
- 10-Q Report Quarterly Report
- SC 13G/A Stake Amended Statement of Ownership
- ARS Other Annual Report to Security Holders
- DEF 14A Proxy Proxy Statement
- UPLOAD Other SEC-generated Letter
- 8-K Event Material agreement · Unregistered share sale · Other events
- 8-K Event Auditor change
- CORRESP Other Correspondence Between Filers and SEC Staff
- 8-K Event Director nominations
- UPLOAD Other SEC-generated Letter
- 10-Q Report Quarterly Report
- NT 10-Q Other NT 10-Q
- 8-K Event Material agreement · Shareholder rights changed · Bylaws or fiscal year change
- EFFECT Other Notice of Effectiveness
- 424B3 Offering Prospectus
- CORRESP Other Correspondence Between Filers and SEC Staff
- S-3/A Offering Registration Statement
- 8-K Event Shareholder rights changed · Bylaws or fiscal year change · Shareholder vote results
- 8-K Event Bylaws or fiscal year change · Regulation FD disclosure
Page 5 of 31 · 604 filings